OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON
Launched by TRANSLATIONAL RESEARCH CENTER FOR MEDICAL INNOVATION, KOBE, HYOGO, JAPAN · Jun 5, 2013
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
Optical frequency domain imaging (OFDI) is a novel, high resolution intravascular imaging modality. Intravascular ultrasound (IVUS) is a widely used conventional imaging modality for achieving optimal stent deployment.
The aim of this randomized study is to evaluate the impact of OFDI guidance for Percutaneous Coronay Intervention (PCI) with drug-eluting stent (DES) as compared with IVUS guidance.
We will enroll 800 patients with a de novo lesion who will undergo PCI with DES as is routine practice. Patients will be rondomely assigned to either OFDI-guided PCI arm or IVUS-guided PCI arm.
...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a de novo lesion (in the native coronary circulation) and planned to undergo drug-eluting stent implantation for indications according to the Japan and USA guidelines
- • Patients aged between 20 and 85 years old
- • Patients who has provided written informed consent
- Exclusion Criteria:
- • Patients with Acute Myocardial Infarction (AMI) within 3 months
- • Patients with cardiogenic shock
- • Patients with chronic heart failure
- • Patients with renal failure (eGFR \<= 30 ml/min/1.73 m2 or Serum creatinine level \>=1.5mg/dL)
- • Patients who are currently enrolled in other clinical trial which has possibility to influence the primary endpoint of OPINION trial.
- • Patients planned use of bare metal stent
- • Patients with 3-vessel diseases
- • Planned surgery within 1 year
- • Patient on dialysis
- * Target lesion such as:
- • Left main coronary artery
- • Aorto-Ostial lesion location within 3mm of the aorta junction
- • Chronic total occlusion
- • Small vessel (reference vessel diameter \<2.5mm)
- • Coronary artery bypass graft
About Translational Research Center For Medical Innovation, Kobe, Hyogo, Japan
The Translational Research Center for Medical Innovation (TRI) in Kobe, Hyogo, Japan, is a pioneering institution dedicated to advancing medical research and innovation. Focused on bridging the gap between laboratory discoveries and clinical applications, TRI fosters a collaborative environment that brings together researchers, clinicians, and industry partners. By facilitating cutting-edge translational studies and clinical trials, TRI aims to accelerate the development of novel therapies and improve patient outcomes. With state-of-the-art facilities and a commitment to excellence, TRI is at the forefront of transforming medical science into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wakayama, Wakayama Prefecture, Japan
Patients applied
Trial Officials
Takashi Akasaka, MD, PhD
Principal Investigator
Wakayama Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials